ATC Group: J06BB Specific immunoglobulins

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J06BB in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J06 Immune sera and immunoglobulins
3 J06B Immunoglobulins
4 J06BB Specific immunoglobulins

Group J06BB contents

Code Title
J06BB01 Anti-D (rh) immunoglobulin
J06BB02 Tetanus immunoglobulin
J06BB03 Varicella/zoster immunoglobulin
J06BB04 Hepatitis B immunoglobulin
J06BB05 Rabies immunoglobulin
J06BB06 Rubella immunoglobulin
J06BB07 Vaccinia immunoglobulin
J06BB08 Staphylococcus immunoglobulin
J06BB09 Cytomegalovirus immunoglobulin
J06BB10 Diphtheria immunoglobulin
J06BB11 Hepatitis A immunoglobulin
J06BB12 Encephalitis, tick borne immunoglobulin
J06BB13 Pertussis immunoglobulin
J06BB14 Measles immunoglobulin
J06BB15 Mumps immunoglobulin
J06BB19
J06BB30 Combinations

Active ingredients in J06BB

Active Ingredient

Anthrax immuneglobulin is a human immune globulin that is used in combination with antibiotics to treat anthrax. Anthrax immunoglobulin binds to protective antigen (PA) to prevent PA mediated cellular entry of anthrax edema factor and lethal factor.

Human anti-D immunoglobulin contains specific antibodies (IgG) against the Rh(D) antigen of human erythrocytes. It can also contain antibodies to other Rh antigens, e.g. anti-Rh C antibodies. The mechanism by which anti-D immunoglobulin suppresses immunisation to Rh(D) positive red cells is not known.

Cytomegalovirus immunoglobulin is used as a CMV-specific polyclonal immunoglobulin preparation that binds to CMV surface antigens thereby neutralizing the potential of CMV from entering host cells and presenting the CMV particle for phagocytosis. Furthermore, cytomegalovirus immunoglobulin can activate CMV-reactive immune cells for long-lasting CMV-specific immune responses.

Human hepatitis B immunoglobulin solution for infusion contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against hepatitis B virus surface antigen (HBs). It is used for the immunoprophylaxis of hepatitis B and the prevention of hepatitis B virus re-infection after liver transplantation for hepatitis B induced liver failure.

Human rabies immunoglobulin contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against rabies virus. Human Rabies Immunoglobulin must always be used in combination with a rabies vaccine.

Human varicella zoster immunoglobulin contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against varicella-zoster virus. It is used for prophylaxis against varicella zoster virus (VZV) infection.

Human tetanus immunoglobulin contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against the toxin produced by the bacteria clostridium tetanus.

Vaccinia immunoglobulin provides passive immunity for individuals with complications to vaccinia virus vaccination. The exact mechanism of action is not known.

Related product monographs

Document Type Information Source  
 CYTOGAM Solution for infusion MPI, US: SPL/Old FDA, National Drug Code (US)
 CYTOTECT CP BIOTEST Solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 HEPAGAM B Solution for infusion MPI, US: SPL/PLR FDA, National Drug Code (US)
 HEPATECT CP Solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 HYPERHEP B Solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 HYPERRAB Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 HYPERRHO S/D FULL DOSE Solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 HYPERTET Solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 RHESONATIV Solution for injection MPI, EU: SmPC Health Products Regulatory Authority (IE)
 RHOPHYLAC Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 TETAGAM-P Solution for injection MPI, EU: SmPC Health Products Regulatory Authority (IE)
 VARIZIG Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 WINRHO SDF Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 ZUTECTRA Solution for injection MPI, EU: SmPC European Medicines Agency (EU)